Compare PRG & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRG | COLL |
|---|---|---|
| Founded | 2020 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.2B |
| IPO Year | 2020 | 2015 |
| Metric | PRG | COLL |
|---|---|---|
| Price | $36.26 | $34.18 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | $50.00 | ★ $51.40 |
| AVG Volume (30 Days) | 387.0K | ★ 444.9K |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.45% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 0.89 | ★ 1.73 |
| Revenue | ★ $2,409,223,000.00 | $780,567,000.00 |
| Revenue This Year | $23.77 | $8.01 |
| Revenue Next Year | $7.91 | N/A |
| P/E Ratio | $39.92 | ★ $19.44 |
| Revenue Growth | N/A | ★ 23.62 |
| 52 Week Low | $25.80 | $26.72 |
| 52 Week High | $41.14 | $50.79 |
| Indicator | PRG | COLL |
|---|---|---|
| Relative Strength Index (RSI) | 67.66 | 49.11 |
| Support Level | $32.07 | $31.36 |
| Resistance Level | $36.71 | $36.22 |
| Average True Range (ATR) | 1.49 | 1.27 |
| MACD | 0.62 | 0.23 |
| Stochastic Oscillator | 92.84 | 51.01 |
PROG Holdings Inc is a financial technology holding company that provides transparent and competitive payment options to consumers. The company has two reportable segments: Progressive Leasing, an in-store, app-based, and e-commerce point-of-sale lease-to-own solutions provider; and Vive Financial (Vive), an omnichannel provider of second-look revolving credit products. The majority of the revenue of the company is earned through the Progressive Leasing segment.
Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.